FURACIN
LOE ApproachingNDATOPICALOINTMENT
Approved
Oct 1945
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FURACIN is a topical ointment small molecule approved in 1945 for wound and burn care. The product's exact mechanism of action and clinical indications are not publicly detailed in available data, but topical antimicrobial ointments of this class are typically used to prevent infection in minor wounds, burns, and ulcers. It represents a legacy product with established clinical utility in dermatology and wound management.
LOE Approaching
With LOE approaching and legacy status, the brand team is likely in defensive/maintenance mode with minimal commercial growth investment and a small, specialized sales footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FURACIN offers limited career growth due to its legacy status and LOE-approaching lifecycle. Roles on this product are primarily focused on portfolio management, supply continuity, and regulatory maintenance rather than innovation or commercial expansion.
Brand Manager (legacy)Supply Chain Specialist
Worked on FURACIN at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.